Ownership Summary
According to SEC filings for the period ending September 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) is held by 7 institutional firms.
- Institutional ownership in Apimeds Pharmaceuticals US edged up to 3.0% in September 2025, compared to 2.9% in June 2025.
- Institutional share ownership changed by 1121217.65% QoQ, while the number of institutional owners saw an unavailable change YoY.
- Of these 7 institutional investors, 6 increased their holdings in Apimeds Pharmaceuticals US, while 0 of them reduced positions, and 1 investors maintained their exposure.
- The total number of shares held by institutions in Apimeds Pharmaceuticals US increased to 381.25K as of September 2025, a net change of up by 381.21K shares quarter on quarter, and down N/A shares year over year.
- The top institutional stake in Apimeds Pharmaceuticals US as of September 30, 2025 belongs to Hemenway Trust Co LLC, which owns 250.00K shares, or 1.96% of the company.
- Among the most significant buyers of Apimeds Pharmaceuticals US during September 2025 were Hemenway Trust Co LLC (250.00K), VANGUARD GROUP INC (58.99K), GEODE CAPITAL MANAGEMENT, LLC (30.75K), RENAISSANCE TECHNOLOGIES LLC (27.89K), HRT FINANCIAL LP (13.57K).
- The top 7 institutional holders of Apimeds Pharmaceuticals US for the quarter ending September 2025 included Hemenway Trust Co LLC (250.00K), VANGUARD GROUP INC (58.99K), GEODE CAPITAL MANAGEMENT, LLC (30.75K), RENAISSANCE TECHNOLOGIES LLC (27.89K), HRT FINANCIAL LP (13.57K), BANK OF AMERICA CORP /DE/ (29), JPMORGAN CHASE & CO (8).